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Chronic myeloid leukemia developing after transplantation of solid organs and concomitant immunosuppression is a rare but still
significant clinical phenomenon.We here describe an additional case of a 62-year-oldmale patient developingCML after orthotopic
heart transplantation and medication with cyclosporine A, mofetil-mycophenolate, and steroids. Initial antileukemic therapy was
imatinib at a standard dose and within 15 months of therapy a complete cytogenetic response was noted. In this report we discuss
the clinical implications of these rare but biologically important cases.
1. Introduction
Secondary malignancies following solid organ transplanta-
tion (SOT) and immunosuppressive therapy are becoming
an emerging issue as total transplant numbers are increasing,
the overall survival of organ recipients is improving, and
an increasing proportion of organ recipients is of older age,
when cancer is more often diagnosed. Probably, the best
studied scenario in this setting is the association of EBV
and posttransplantation lymphoproliferative diseases [1]. But
also squamous cell carcinomas and Kaposi sarcomas as well
as specific myeloid malignancies, notably myelodysplastic
syndromes and acute myeloid leukemia, have been observed
more frequently in patients following solid organ transplan-
tation [2, 3]. In addition, after the first report by Battin et al.
(1976), a remarkable number of case reports describing cases
of chronic myeloid leukemia (CML) following solid organ
transplantation and immunosuppressionwere published over
the past decades ([4–27], Table 1).
In CML the BCR-ABL1 fusion gene, caused by a typical
t(9;22)(q34;q11) chromosomal translocation, is the patho-
genic driver of the disease leading to enhanced proliferation
and left shift but also is used as a target to monitor minimal
residual disease by quantitative reverse-transcription quan-
titative polymerase chain reaction (rt-PCR) analyses [28].
On the protein level, the bcr-ablp210 oncoprotein has become
the target structure for specific therapies by tyrosine kinase
inhibitors such as imatinib, nilotinib, and/or dasatinib in the
first-line setting and additionally bosutinib and ponatinib
beyond initial treatment [29]. There are conflicting data
whether BCR-ABL1 is the only oncogenic lesion that is
needed to cause chronic phase CML or if other, yet uniden-
tified, mutations are involved. In this regard the sporadic
identification of low levels of BCR-ABL1 transcripts in healthy
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individuals was of note [30, 31]. The general interpretation of
these findings was that in healthy individuals the occurrence
of oncogenic mutations, including BCR-ABL1, may occur but
is under the control of an effective immune surveillance.
Thus, CML developing in patients following SOT may
be triggered by the effects of concomitant application of
immunosuppressive drugs. In line with this hypothesis we
previously compared by rt-PCR the BCR-ABL1 status in
patients following SOTbutwithoutCMLand indeed detected
5% low-level PCR positivity in these patients as compared
to none in a control group without immunosuppression [21].
Finally, in a recently published article the risk to developCML
in patients after SOT was calculated to be more than 20-fold
higher as in the normal population [26].
In this paper we describe another patient with chronic
phase CML following orthotopic heart transplantation and
immunosuppression. As in our previous article we discussed
the various biological mechanisms that may contribute to
CML following immunosuppression; we here provide an
overview on all published cases and focus on individual
aspects of the clinicalmanagement in this specific cohort [21].
2. Case Presentation
We here report on a caucasian male with dilated cardiomy-
opathy, who underwent in November 2010 as a 61-year-
old patient an orthotopic bicaval heart transplantation at
the Deutsches Herzzentrum Berlin following left ventricular
assist device (HeartMate II) implantation in September 2009
due to cardiogenic shock. Due to impaired graft function
a primary intra-aortic balloon pump was implanted. Trans-
plantation was done in a CMV-positive recipient with a
heart graft from a CMV-positive donor. Induction therapy
was performed using Thymoglobulin (1.5mg/kg). Posttrans-
plant maintenance immunosuppressive therapy consisted
of cyclosporine A (4mg/kg), mofetil-mycophenolate (2-3 g
daily), and prednisolone (tapering regimen, 0.15mg/kg).
Concomitant medication included pantozol, amlodipine,
ramipril, magnesium, allopurinol, torasemide, fluvastatine,
and Ca-D3. Two serologic CMV replications were treated
with ganciclovir i.v. The cardiovascular risk profile prior to
transplantation included tobacco use, arterial hypertension,
and male gender.
During a routine follow-up visit inMarch 2013 leukocyto-
sis of 33.000/𝜇L, thrombocytosis of 655.000/𝜇L, and anemia
of 11.2 g/dLwere noted.The differential blood count wasmye-
locytes 6%, metamyelocytes 2%, bands 5%, segmented gran-
ulocytes 75%, eosinophils 2%, basophils 2%, monocytes 5%,
and lymphocytes 3%. Accordingly, a bone marrow analysis
was done that revealed elevation ofmegakaryocytes and a dis-
balance between granulopoiesis and erythropoiesis of 4 : 1 but
no elevation of blasts or promyelocytes. Conventional cyto-
genetics analysis demonstrated the typical t(9;22)(q34;q11)
translocation in all analysed nuclei and a multiplex PCR
confirmed the presence of BCR-ABL transcripts establishing
the diagnosis of chronic phase chronic myeloid leukemia. No
hepatosplenomegaly was present allocating this patient into
the low-risk category by EUTOS-score [28].
As there are currently three tyrosine kinase inhibitors
(imatinib, nilotinib, and dasatinib) with approval for the first-
line treatment of CML, the choice of therapy was primarily
made on the basis of the individual tolerability profile. As
nilotinib is associatedwith a cardiovascular risk and dasatinib
is linked to pleural and pericardial effusion and pulmonary
artery hypertension, imatinib 400mg was chosen [32, 33].
Imatinib was well tolerated and within 3 months nor-
malisation of peripheral blood cell counts, compatible with
a complete hematologic response, was observed. At the
time of CML diagnosis maintenance immunosuppression
was switched to a double regimen (cyclosporine A trough
level 100–120 ng/mL and prednisolone 0.15mg/kg). A bone
marrow analysis taken 15 months after start of imatinib
showed a complete cytogenetic remission. However, in 10 out
of 25 otherwise normal analysed metaphases a loss of the y
chromosome was detected. So far, imatinib is well tolerated
in this patient without any drug related adverse events.
Echocardiographic examinations done at diagnosis of
CML and 14 months after initiation of imatinib documented
a left ventricular ejection fraction of at least 60% indicating
no cardiotoxicity of tyrosine kinase inhibitor therapy.
3. Discussion
The development of hematologic malignancies is a rare clin-
ical complication in the post- organ-transplant population
and most frequently occurs as Non-Hodgkin-Lymphoma
(PTLD).
Since the first description by Battin et al. (1976) altogether
34 patients developing CML after SOT were reported, pri-
marily as case reports, and 15 of these cases were published
within the past 5 years, indicating a growing interest in this
phenomenon [4–27]. In amost recent report the frequency of
CML developing in SOT patients was calculated relating the
total transplant numbers in a single centre and the number
of CML cases observed in this group of patients to the
age- and gender-matched US population [26]. Despite the
low denominator of 3089 individuals in this study an age
adjusted incidence rate of 34.7 per 100 000 was observed that
significantly (𝑃 < 0.0001) exceeds the US incidence of 1.6 per
100 000 [26].Thus, under the assumption that SOT carries an
elevated risk of CML, these numbers will eventually increase
in the future as both the total number of transplants and the
age of organ recipients are increasing.
Generally, two types of mechanisms must be differen-
tiated in the clinical setting of a de-novo posttransplant
malignancy: (1) the unfrequent cases of preexisting malig-
nancies that are transferred with the donor organ and (2)
malignancies manifesting after initiation of immunosup-
pressive therapy. In the first case HLA-typing or molecular
clonal testing of neoplastic tissue can be applied to rule out
donor derived neoplasms while in the latter case the exact
pathomechanism is not understood but impaired immune
surveillance together with intrinsic mutagenic potential may
play a significant role. But also the effect of either infectious
(viral) or toxic (immune suppressive drugs) factors could
contribute as an extrinsic cause of transformation. In this
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regard the observation ofDNA lesions caused by azathioprine
in combination with UVA radiation is of note [34]. Still, the
exact role of the immunosuppressive drugs in the evolution
of posttransplantation malignancies needs to be elucidated,
but it is of interest that these cases continue to appear while
azathioprine is being more and more replaced by alternative
drugs such as mycophenolate mofetil and tacrolimus.
Several aspects in the setting of CML developing after
SOT are of note.
With the various tyrosine kinase inhibitors that are
currently available for the first-line treatment the prognosis
of CML has improved dramatically over the past 15 years
[28]. To what extent the specific clinical setting of patients
with CML following SOT may impact response is unclear.
Certainly, the underlying disease leading to transplantation,
potential drug interactions, and a potentially low clinical
performance status could negatively impact response and
survival rates in individual patients. On the other hand due
to the more frequent visits of patients following SOT patients
developing CML may eventually be recognised earlier and
already at a lower risk. This hypothesis is reflected by the
observation that in our patient as well as in many of the
currently published cases WBC were relatively low (<35.000
per 𝜇L) when CML was diagnosed (Table 1).
Probably because of relative short follow-up intervals in
none of the reports presented here deep molecular responses
that would allow drug discontinuations were reported. How-
ever, as immunological mechanisms are currently discussed
to be involved in patients stopping TKI therapy after long-
term molecular remission, we hypothesize that in patients
with CML following immunosuppression fewer patients
would remain BCR-ABL negative after discontinuation as
long as immunosuppression is continued.
To our knowledge we here describe the fourth patient
with CML following heart transplantation and the third
case of this kind that was treated with a tyrosine kinase
inhibitor [10, 24]. But other than in the cases reported by
Sbenghe et al. and Menon et al. who received tacrolimus in
addition to mofetil-mycophenolate in our case cyclosporine
was given [24, 27]. However, the significance of the various
immunosuppressive drugs given in these patients is still
unclear. The case reported by Menon et al. is of specific
interest as it describes a secondary CML developing after
acute myeloid leukemia [27]. In this pediatric case heart
transplantation was carried out because of anthracycline-
induced cardiomyopathy [27]. With the exception of a past
case by Frist et al. all other cases of CML following heart
transplantation are characterized by a relatively short latency
of 9 to 16 months [10, 24, 27]. This observation could be
associated to the relatively dose intensive immunosuppressive
regimens used in heart transplantation.
Most of the published cases were treated with imatinib
as first-line TKI. In general, all three currently approved
first-line options (imatinib, nilotinib, and dasatinib) can
be chosen as well in SOT patients. However, as the toxi-
city profiles of the second generation TKIs dasatinib and
nilotinib include immunosuppression, atherosclerotic events,
pulmonary artery hypertension, and pleural effusion, an
initial trial with imatinib, despite its less favourable response
rates, may be the preferred treatment option in many of these
patients [32, 33]. As in our patient numerous cardiovascular
risk factors were present and already a major cardiac inter-
vention was performed, we also preferred imatinib over a
second generation TKI as first-line option.
In summary, CML following immunosuppressive therapy
beyond its clinical implications is an interesting model of
immune surveillance in tumor biology. As there are only few
cases of Ph1 chromosome negative chronicmyeloproliferative
neoplasms arising after immunosuppression, we suspect this
phenomenon to be specifically linked to CML. We believe
that both preclinical and clinical investigations that address
the specific mechanisms of immunosuppressive drugs and
the acquisition of the t(9;22)(q34;q11) could be of interest.
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